Chemotherapy regimen of study SWOG-9400
| Agent . | Dose and route . | Days . | Notes . |
|---|---|---|---|
| Induction part 1 | |||
| Daunorubicin | 60 mg/m2 IV | 1, 2, 3 | |
| Vincristine | 1.4 mg/m2 PO | 1, 8, 15, 22 | Maximum 2 mg per administration |
| Prednisone | 60 mg/m2 per day IV | 1-42 | Full dose to day 28, taper to day 42 |
| PEG-L-asparaginase | 2000 units/m2 IM | 15 | Until protocol amendment of September 1, 1999 |
| L-Asparaginase | 10 000 units/d IV or IM | 15-24 | After protocol amendment of September 1, 1999 |
| Induction part 2 (patients with persistent leukemia on day 21) | |||
| Daunorubicin | 60 mg/m2 IV | 22, 23 | |
| Vincristine | 1.4 mg/m2 PO | 29, 36 | Maximum 2 mg per administration |
| Prednisone | 60 mg/m2 per day IV | Through day 42 | |
| PEG-L-asparaginase | 2000 units/m2 IM | Day 38 | Until protocol amendment of September 1, 1999, only |
| Consolidation | |||
| Cyclophosphamide | 650 mg/m2 IV | 1, 15, 29 | |
| Ara-C | 75 mg/m2 per day IV push | 2-5, 9-12, 16-19, 23-26 | |
| 6-Mercaptopurine | 60 mg/m2 PO | 1-28 | |
| Methotrexate | 10 mg/m2 IT or intraventricular | 2, 9, 16, 23 | |
| Maintenance course 1 | |||
| 6-Mercaptopurine | 60 mg/m2 per day PO | 1-63 | |
| Methotrexate | 20 mg/m2 per week PO | 1-63 | |
| Maintenance course 2 | |||
| Vincristine | 1.5 mg/m2 IV | 1, 8, 15, 22 | Maximum 2 mg per administration |
| Adriamycin | 25 mg/m2 IV | 1, 8, 15, 22 | |
| Dexamethasone | 10 mg/m2 PO | 1-28 | |
| Maintenance course 3 | |||
| Cyclophosphamide | 650 mg/m2 IV | 1 | |
| Thioguanine | 60 mg/m2 PO | 1-14 | |
| Ara-C | 75 mg/m2 IV push | 3-6, 10-13 | |
| Maintenance course 4 | |||
| 6-Mercaptopurine | 60 mg/m2 per day PO | Daily for 2 y | |
| Methotrexate | 20 mg/m2 per week PO | Weekly for 2 y | |
| Agent . | Dose and route . | Days . | Notes . |
|---|---|---|---|
| Induction part 1 | |||
| Daunorubicin | 60 mg/m2 IV | 1, 2, 3 | |
| Vincristine | 1.4 mg/m2 PO | 1, 8, 15, 22 | Maximum 2 mg per administration |
| Prednisone | 60 mg/m2 per day IV | 1-42 | Full dose to day 28, taper to day 42 |
| PEG-L-asparaginase | 2000 units/m2 IM | 15 | Until protocol amendment of September 1, 1999 |
| L-Asparaginase | 10 000 units/d IV or IM | 15-24 | After protocol amendment of September 1, 1999 |
| Induction part 2 (patients with persistent leukemia on day 21) | |||
| Daunorubicin | 60 mg/m2 IV | 22, 23 | |
| Vincristine | 1.4 mg/m2 PO | 29, 36 | Maximum 2 mg per administration |
| Prednisone | 60 mg/m2 per day IV | Through day 42 | |
| PEG-L-asparaginase | 2000 units/m2 IM | Day 38 | Until protocol amendment of September 1, 1999, only |
| Consolidation | |||
| Cyclophosphamide | 650 mg/m2 IV | 1, 15, 29 | |
| Ara-C | 75 mg/m2 per day IV push | 2-5, 9-12, 16-19, 23-26 | |
| 6-Mercaptopurine | 60 mg/m2 PO | 1-28 | |
| Methotrexate | 10 mg/m2 IT or intraventricular | 2, 9, 16, 23 | |
| Maintenance course 1 | |||
| 6-Mercaptopurine | 60 mg/m2 per day PO | 1-63 | |
| Methotrexate | 20 mg/m2 per week PO | 1-63 | |
| Maintenance course 2 | |||
| Vincristine | 1.5 mg/m2 IV | 1, 8, 15, 22 | Maximum 2 mg per administration |
| Adriamycin | 25 mg/m2 IV | 1, 8, 15, 22 | |
| Dexamethasone | 10 mg/m2 PO | 1-28 | |
| Maintenance course 3 | |||
| Cyclophosphamide | 650 mg/m2 IV | 1 | |
| Thioguanine | 60 mg/m2 PO | 1-14 | |
| Ara-C | 75 mg/m2 IV push | 3-6, 10-13 | |
| Maintenance course 4 | |||
| 6-Mercaptopurine | 60 mg/m2 per day PO | Daily for 2 y | |
| Methotrexate | 20 mg/m2 per week PO | Weekly for 2 y | |
IV indicates intravenously; PO, orally; IM, intramuscularly; and IT, intrathecally.